Skip to main content

Table 4 Adverse events

From: Efficacy and safety of edoxaban tosylate hydrate 15 mg in the prevention of venous thromboembolism in patients with impaired renal function after orthopedic surgery of the lower extremities

  Edoxaban 15 mg (n = 23) Edoxaban 30 mg (n = 209) p value OR (95% CI)
Major bleeding 0 0 1.00  
CRNM bleeding 0 2 (1%) 1.00  
Minor bleeding 0 7 (3.3%) 1.00  
AST or ALT level ≥ 1.5 × ULN 4 (17.4%) 26 (12.4%) 0.51 1.48 (0.34–4.95)
AST or ALT level ≥ 3 × ULN 3 (13.0%) 14 (6.7%) 0.39 2.07 (0.35–8.37)
  1. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; OR, odds ratio; ULN, upper limit of normal